?Winning the War Against Rheumatoid Arthritis?
RA is a condition that forces half of patients to become disabled from the work force within five to ten years? and reduces life expectancy by as much as 18 years. RA affects about one per cent of the world's adult population, most commonly women between the ages of 30 and 50.
The good news is that a tremendous amount of progress has been made within the last ten years in identifying patients earlier and treating the disease more aggressively. Patients with RA, if treated appropriately, can lead a relatively normal life. This is in stark contrast to the wheel-chair bound existence common as recently as 20 years ago!
Experts in the field consider early rheumatoid arthritis to be a medical emergency with mortality and morbidity equal to that for diabetes, asthma, heart disease, and other life-threatening conditions.
Rheumatoid arthritis attacks the joints in a symmetric fashion (both sides of the body affected equally) with the most common areas being the hands, wrists, ankles, knees, and feet. In addition to the swelling and pain, patients with RA often have profound fatigue and stiffness.
Rheumatoid arthritis is an autoimmune disease that attacks not only joints, but internal organs such as the blood vessels, lungs, heart, and eyes. Patients with RA are at increased risk for heart attack, stroke, and lymphoma.
Since many other types of arthritis such as gout, lupus, and osteoarthritis can look like RA a careful diagnostic approach is needed.
Laboratory testing has its pitfalls. The rheumatoid factor, a blood test found to be positive in about 80 per cent of individuals with RA, may also be positive in other disease conditions. Couple that with the fact that 20 per cent of patients with RA will be rheumatoid factor negative, then it becomes clear a diagnosis should not hinge on the results of blood tests alone.
Imaging procedures can also be misleading. Conventional x-rays often miss the erosions found with early disease. Newer imaging technologies such as magnetic resonance imaging (MRI) and ultrasound are much more sensitive.
After the diagnosis is made, there is even more hope for a patient today. In the past, non steroidal anti-inflammatory drugs (NSAIDS) used to be considered a cornerstone of therapy. That is no longer true.
Disease-modifying anti-rheumatic drugs (DMARDS) are being used earlier. Among the DMARDS currently being used are methotrexate, leflunomide (Arava), azathioprine (Imuran), sulfasalazine (Azulfidine), cyclosporine, and hydroxychloroquine (Plaquenil). These drugs attack the immune cells responsible for chronic inflammation. While DMARDS alone in combination are effective, they are relatively non-specific. Often, combinations of DMARDS are required.
Biologic Response Modifiers (BRMS) can target the disease more specifically than DMARDS. RA is a disease that is dependent on the signaling that occurs between immune cells. The signaling takes place through the use of special chemical messengers called cytokines. BRMS act at both the cytokine (chemical messenger) as well as the cellular level allowing the disease to be better controlled and in some instances put into remission.
Biologic response modifiers, which include drugs that suppress tumor necrosis factor (TNF), appear to be particularly effective.
Tumor necrosis factor is a protein that is produced by the immune cells. TNF is the major culprit responsible for inflammation-inducing damage. By block the effects of TNF, better control of RA can be achieved.
Three anti-TNF drugs are currently available: etanercept (Enbrel), adalimumab (Humira), and infliximab (Remicade). Another biologic drug, anakinra (Kineret) blocks interleukin, a different cytokine.
These drugs allow patients to have their disease controlled to such an extent that most are able to enjoy a normal work and leisure existence.
On the horizon are other biologic drugs that work at different points in the immune system- on different cytokines and on different pathways- to allow even greater as well as more specific control of disease. Since rheumatoid arthritis is a disease with many different cytokine and cellular mechanisms responsible for damage, attacking the disease at different points makes sense. In the future it may be possible to identify patients through specific tissue signals (called "biomarkers"). These biomarkers will allow physicians to type patients and give patients the specific therapy that will work best for them. Once that is achieved, the possibility of a cure becomes a reality.
Everything, though, starts with early accurate diagnosis. If damage is allowed to occur the chances for remission drop dramatically!
Dr. Wei (pronounced "way") is a board-certified rheumatologist and Clinical Director of the nationally respected Arthritis and Osteoporosis Center of Maryland. He is a Clinical Assistant Professor of Medicine at the University of Maryland School of Medicine and has served as a consultant to the Arthritis Branch of the National Institutes of Health. He is a Fellow of the American College of Rheumatology and the American College of Physicians. For more information on arthritis and related conditions, go to: http://www.arthritis-treatment-and-relief.com
Latest News
 WNCT | Three Employees Fired After Patient Chokes on Medicine, Dies FOXNews - GOLDSBORO, NC — North Carolina officials have fired three employees and disciplined others in the death of a patient who was neglected for more than 22 ... Firings a good first step in neglect case |
 OverTheLimit.info | When the Caregiver Becomes the Patient Washington Post, United States - The study was published in the November issue of the Journal of General Internal Medicine. "Our findings opened our minds to the fact that society needs to ... Ginko Results On Memory Contradict Studies, Chinese Medicine Ginkgo biloba doesn't prevent dementia, study finds Ginkgo can't prevent Alzheimer's in those older than 75 |
Research and Markets: This Global Research Report in Medicine and ... MarketWatch - Nanomaterials, nanophotonics, nanoelectronics and nanoscience in medicine & biology represent the largest concentration of R&D. ... |
Personal medicine is goal of Eli Lilly & Co. Arizona Republic, AZ - Still, Taurel said the role of personalized medicine has come at a slower pace than some had hoped for after scientists completed the Human Genome Project. ... |
Old Crow Medicine Show to perform Dec. 3 Boone Mountain Times, USA - Once playing for donations on the streets of Nashville and later headlining the city’s historic Ryman Auditorium, Old Crow Medicine Show has come full ... Old Crow Medicine Show promises energetic set |
Costa Rica arrests 6 for medicine shipments to US The Associated Press - SAN JOSE, Costa Rica (AP) — A Costa Rican official says two Americans and four others have been arrested for allegedly sending restricted pharmaceutical ... |
Review: Band brings medicine and show to The Depot Salt Lake Tribune, United States - By Lee Thomsen The Nashville quintet Old Crow Medicine Show delivered a traveling hoedown -- equal parts bluegrass, jug band and jam band -- at The Deport ... |
SonoSite Introduces S-FAST Vascular Access Option for Safer ... MarketWatch - It's difficult to imagine practicing emergency medicine today without ultrasound guidance." "Using ultrasound reveals anatomy previously unseen. ... |
Carlos V. Paya, MD, PhD, to Join Elan as Company President MarketWatch - ... which began with his acceptance into the Mayo Graduate School of Medicine in 1984 and concluded with a six-year tenure as Professor of Medicine, ... |
 TVNZ | Outgoing HHS Secretary Offers Advice For Advancing Personalized ... Pharmacogenomics Reporter (registration), NY - Leavitt is largely regarded as a champion for the advancement of genetics and genomics research by personalized medicine stakeholders. ... Video: FDA to Open Offices in China, India FDA's 1st foreign branch opened US food, drug regulator opens first overseas office in Beijing |
Resources
-
Sorry Currently Unavailable